These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1970 related articles for article (PubMed ID: 30360816)

  • 1. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Twist and Wnt signaling pathways in metastatic breast cancer.
    Glackin CA
    Maturitas; 2014 Sep; 79(1):48-51. PubMed ID: 25086726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
    Roberts CM; Shahin SA; Wen W; Finlay JB; Dong J; Wang R; Dellinger TH; Zink JI; Tamanoi F; Glackin CA
    Nanomedicine; 2017 Apr; 13(3):965-976. PubMed ID: 27890656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis.
    Finlay J; Roberts CM; Lowe G; Loeza J; Rossi JJ; Glackin CA
    Biomed Res Int; 2015; 2015():382745. PubMed ID: 25759817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
    Bahar E; Kim JY; Kim HS; Yoon H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.
    Shahin SA; Wang R; Simargi SI; Contreras A; Parra Echavarria L; Qu L; Wen W; Dellinger T; Unternaehrer J; Tamanoi F; Zink JI; Glackin CA
    Nanomedicine; 2018 Jun; 14(4):1381-1394. PubMed ID: 29665439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
    Lee HJ; Li CF; Ruan D; Powers S; Thompson PA; Frohman MA; Chan CH
    Mol Cell; 2016 Sep; 63(6):1021-33. PubMed ID: 27618486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
    Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
    J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
    Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
    Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
    Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
    J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA
    Tu SH; Chiou YS; Kalyanam N; Ho CT; Chen LC; Pan MH
    Food Funct; 2017 Mar; 8(3):1067-1079. PubMed ID: 28145547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer.
    Ban Y; Zou Y; Liu Y; Lee S; Bednarczyk RB; Sheng J; Cao Y; Wong STC; Gao D
    Elife; 2024 Sep; 12():. PubMed ID: 39259576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70
    Ma J; Kala S; Yung S; Chan TM; Cao Y; Jiang Y; Liu X; Giorgio S; Peng L; Wong AST
    Mol Ther; 2018 Jan; 26(1):70-83. PubMed ID: 29241971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twist-BRD4 complex: potential drug target for basal-like breast cancer.
    Shi J; Cao J; Zhou BP
    Curr Pharm Des; 2015; 21(10):1256-61. PubMed ID: 25506891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
    Yang Y; Wang G; Zhu D; Huang Y; Luo Y; Su P; Chen X; Wang Q
    Int J Oncol; 2017 Aug; 51(2):515-524. PubMed ID: 28627611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomegranate Extract Alters Breast Cancer Stem Cell Properties in Association with Inhibition of Epithelial-to-Mesenchymal Transition.
    Nallanthighal S; Elmaliki KM; Reliene R
    Nutr Cancer; 2017 Oct; 69(7):1088-1098. PubMed ID: 28976208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
    Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
    Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twist: a molecular target in cancer therapeutics.
    Khan MA; Chen HC; Zhang D; Fu J
    Tumour Biol; 2013 Oct; 34(5):2497-506. PubMed ID: 23873099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.